Arbidol as a broad-spectrum antiviral: an update.

Arbidol as a broad-spectrum antiviral: an update.
复制标题

DOI:
10.1016/j.antiviral.2014.04.006
复制
发表时间:
2014-07
期刊:
影响因子:
7.6
通讯作者:
Pécheur EI
Pécheur EI
中科院分区:
医学2区
文献类型:
--
作者:
Blaising J;Polyak SJ;Pécheur EI

文献摘要

参考文献

被引文献

相似文献

阿比朵尔(ARB)在俄罗斯和中国获得许可,用于治疗流感和其他病毒感染。ARB抑制一系列病毒病原体,无论是否有包膜。ARB显示出与脂膜和病毒或细胞蛋白的双重结合活性。它阻断病毒在细胞膜内的内吞作用和复制。阿比朵尔(ARB)是一种俄罗斯制造的小吲哚衍生物分子,在俄罗斯和中国获得许可,用于预防和治疗流感和其他呼吸道病毒感染。它还表现出对其他病毒的抑制活性,无论是否有包膜,这些病毒导致新出现的或全球流行的传染病,如B肝炎和丙型肝炎、胃肠炎、出血热或脑炎。在这篇综述中,我们将探讨ARB作为一种广谱抗病毒药物的可能性和相关性,经过仔细检查其理化性质,药代动力学,毒性和分子作用机制。最近的研究表明,ARB与膜和蛋白质中芳香族氨基酸的双重相互作用可能是其广谱抗病毒活性的核心。这可能会影响病毒本身,和/或细胞功能或病毒-细胞相互作用的关键步骤,从而将ARB定位为直接作用的抗病毒剂(DAA)和宿主靶向剂(HTA)。在最近的动物和人类研究的背景下,我们将讨论ARB在各种病毒感染中的前瞻性临床应用。
Arbidol (ARB) is licensed in Russia and China for the treatment of influenza and other viral infections. ARB inhibits a large panel of viral pathogens, enveloped or not. ARB displays a dual binding activity to lipid membranes and to viral or cellular proteins. It blocks viral endocytosis and replication in membranous intracellular compartments. Arbidol (ARB) is a Russian-made small indole-derivative molecule, licensed in Russia and China for prophylaxis and treatment of influenza and other respiratory viral infections. It also demonstrates inhibitory activity against other viruses, enveloped or not, responsible for emerging or globally prevalent infectious diseases such as hepatitis B and C, gastroenteritis, hemorrhagic fevers or encephalitis. In this review, we will explore the possibility and pertinence of ARB as a broad-spectrum antiviral, after a careful examination of its physico-chemical properties, pharmacokinetics, toxicity, and molecular mechanisms of action. Recent studies suggest that ARB’s dual interactions with membranes and aromatic amino acids in proteins may be central to its broad-spectrum antiviral activity. This could impact on the virus itself, and/or on cellular functions or critical steps in virus-cell interactions, thereby positioning ARB as both a direct-acting antiviral (DAA) and a host-targeting agent (HTA). In the context of recent studies in animals and humans, we will discuss the prospective clinical use of ARB in various viral infections.
DOI: 10.1371/journal.pbio.0050183
发表时间: 2007-07
期刊: PLoS biology
影响因子: 9.8
作者:
Brandenburg B;Lee LY;Lakadamyali M;Rust MJ;Zhuang X;Hogle JM
通讯作者: Hogle JM
阿比朵尔对乳鼠和体外致命汉坦病毒感染的功效
DOI: 10.1038/aps.2009.53
发表时间: 2009-07-01
影响因子: 8.2
作者:
Deng, Hai-ying;Luo, Fan;Yang, Zhan-qiu
通讯作者: Yang, Zhan-qiu
基于 3D QSAR 研究鉴定具有抗 HBV 活性的新型 5-羟基-1H-吲哚-3-羧酸盐
DOI: 10.1007/s00894-010-0873-7
发表时间: 2011-08-01
影响因子: 2.2
作者:
Chai, Hui-fang;Liang, Xin-xia;Luo, Cheng
通讯作者: Luo, Cheng
DOI: 10.1371/journal.pone.0011479
发表时间: 2010-07-08
期刊: PloS one
影响因子: 3.7
作者:
Bernard E;Solignat M;Gay B;Chazal N;Higgs S;Devaux C;Briant L
通讯作者: Briant L
DOI: 10.1007/s00216-011-5581-3
发表时间: 2012-02
影响因子: 4.3
作者:
Berendsen, Bjorn J. A.;Wegh, Robin S.;Essers, Martien L.;Stolker, Alida A. M.;Weigel, Stefan
通讯作者: Weigel, Stefan